OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy

Launched by ONCOSIL MEDICAL LIMITED · May 1, 2024

Keywords

ClinConnect Summary

The OncoSil Pancreatic Cancer Post-marketing Clinical Registry in Italy is a study designed to look at how well the OncoSil™ device works for patients with locally advanced pancreatic cancer that cannot be surgically removed. This device is used along with standard chemotherapy treatment, specifically gemcitabine-based therapies. The goal of this registry is to gather real-world information about the safety and effectiveness of OncoSil™ as it is used in everyday medical practice.

To participate in this study, patients need to be eligible for OncoSil™ treatment at a facility that follows the approved guidelines. They must also sign a consent form confirming they understand the study. However, patients who are currently involved in other clinical trials or using experimental treatments cannot join this study. Participants can expect to have their treatment monitored closely to help doctors understand how OncoSil™ works in combination with chemotherapy for this type of cancer. Overall, this research aims to improve future care for patients facing this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients who are eligible for and undergo OncoSil™ implantation at an eligible treatment facility according to the approved OncoSil™ System Instructions for Use (IFU), as part of their clinical care.
• • 2. Patients who have completed and signed the Patient Informed Consent Form (PICF) for the OSPRItaly Patient Registry.
• Exclusion Criteria:
• • 1. Patients participating in an interventional clinical study (company or investigator-sponsored).
• • 2. Use of an investigational agent at the time of enrolment.